Novel approaches to the treatment of high-grade sarcoma
Metadata
Show metadataAppears in the following Collection
- Institutt for klinisk medisin [10814]
Abstract
No abstract.List of papers
Paper I: Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, Stenwig AE, Willen H, Holmström T, Follerås G, Brosjö O, Kivioja A, Jonsson K, Monge O, Sæter G. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003, 39; 488-494. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1016/S0959-8049(02)00747-5 |
Paper II: Müller CR, Smeland S, Bauer H, Sæter G, Strander H. Interferon-α as the only adjuvant treatment in high grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol 2005, 44; 475-480. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1080/02841860510029978 |
Paper III: Müller CR, Namløs HM, Bjerner J, Østensen IHG, Sæter G, Smeland S, Bruland Ø, Myklebost O. Characterization of Treatment Response to Interferon-α in Osteosarcoma Xenografts. Not published version, published in: J Cancer Sci Ther 2: 033-042. Published under a Creative Commons Attribution License. The published version of this paper is available at: https://doi.org/10.4172/1948-5956.1000020 |
Paper IV: Müller CR, Paulsen EB, Nordhuis P, Pedeutour F, Sæter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.Int J Cancer, 2007, 121; 199-205. The paper is removed from the thesis in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.1002/ijc.22643 |